Bosutinib-induced osteonecrosis of the jaw in a patient with chronic myeloid leukemia: a case report

Myoken, Yoshinari; Fujita, Yasunori; Imanaka, Ryota; Toratani, Shigeaki

doi:10.1007/s10006-020-00931-x

Cited by 4 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Myoken et al [55] described the case of a 65-year-old male with no prior history of antiresorptive therapy who developed ONJ after being treated with bosutinib for CML for one year. The treatment involved the extraction of the second premolar, which had a periapical lesion and the complete removal of the necrotic bone.…”

Section: Other Tkismentioning

confidence: 99%

See 1 more Smart Citation

Exploring the Impact of Novel Anti-Cancer Therapies on Jaw Osteonecrosis and Other Bones: A Comprehensive Review

Konarski,

Poboży,

Konarska

et al. 2024

JCM

View full text Add to dashboard Cite

Osteonecrosis is a debilitating condition characterized by the loss of blood supply to the bones, leading to bone death. This condition can impact various bones, including the jaw, which significantly affects patients’ quality of life by causing difficulties in swallowing, feeding, chewing, and speaking, along with swollen, painful mucous membranes and chronic sinusitis. Osteonecrosis can arise due to treatment with antiresorptive drugs. However, there is a growing number of reports of osteonecrosis following novel targeted anti-cancer treatments, such as tyrosine kinase inhibitors (TKIs) and biological therapies. The pathogenesis of osteonecrosis is linked to the side effects of the antiangiogenic mechanisms of these medications, leading to a disrupted blood flow. Our review aims to examine recent insights into osteonecrosis triggered by new anti-cancer drugs. Most reports focus on the osteonecrosis of the jaw (ONJ); however, we discovered that some authors have described cases of osteonecrosis affecting the femoral head or elbow following novel anti-cancer treatments. Prevention is a key component in managing osteonecrosis. Therefore, a comprehensive risk assessment should always be performed before and during anti-cancer therapy.

show abstract

Section: Other Tkismentioning

confidence: 99%

“…The primary way bosutinib causes ONJ might be due to its harmful effects on osteoclasts and osteoblasts. This is because it blocks the tyrosine kinase Src/Abl pathway, leading to a disruption in bone remodeling [55].…”

Section: Other Tkismentioning

confidence: 99%